533 related articles for article (PubMed ID: 11441105)
21. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
[TBL] [Abstract][Full Text] [Related]
22. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
Delgado M; Ganea D
J Biol Chem; 1999 Nov; 274(45):31930-40. PubMed ID: 10542221
[TBL] [Abstract][Full Text] [Related]
24. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
25. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6.
Delgado M; Martinez C; Pozo D; Calvo JR; Leceta J; Ganea D; Gomariz RP
J Immunol; 1999 Jan; 162(2):1200-5. PubMed ID: 9916753
[TBL] [Abstract][Full Text] [Related]
26. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
27. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.
Ganea D; Delgado M
Crit Rev Oral Biol Med; 2002; 13(3):229-37. PubMed ID: 12090463
[TBL] [Abstract][Full Text] [Related]
29. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
30. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Feb; 164(3):1200-10. PubMed ID: 10640731
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages.
Martínez C; Delgado M; Pozo D; Leceta J; Calvo JR; Ganea D; Gomariz RP
J Leukoc Biol; 1998 May; 63(5):591-601. PubMed ID: 9581803
[TBL] [Abstract][Full Text] [Related]
33. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.
Delgado M
J Biol Chem; 2003 Jul; 278(30):27620-9. PubMed ID: 12754213
[TBL] [Abstract][Full Text] [Related]
35. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
38. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes.
Delgado M; Ganea D
Ann N Y Acad Sci; 2000; 921():55-67. PubMed ID: 11193880
[TBL] [Abstract][Full Text] [Related]
39. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes.
Martinez C; Delgado M; Gomariz RP; Ganea D
J Immunol; 1996 Jun; 156(11):4128-36. PubMed ID: 8666779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
